Tenax Therapeutics TENX 深 沪
已收盘 07-02 16:00:00 美东时间
15.46
+2.170
+16.33%
华盛通- 最 高15.49
- 今 开14.66
- 成交量 389.47万股
- 最 低 14.002
- 昨 收 13.29
- 总市值 4.10亿
- 52周最高 18.38
- 市盈率 静 --
- 换手率 14.68%
- 52周最低 5.7663
- 委 比 -32.56%
- 总股本 2652.52万
- 历史最高 274560.00
- 量 比 2.24
- 振 幅 11.20%
- 历史最低 4.63
- 每 手 1
- 风险率 3.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>Tenax Therapeutics, Inc. awarded inducement option awards to three newly hired non-executive employees on July 1, 2026, as material inducements to their employment. The employees received non-qualified stock options to purchase 160,000 shares of the Company's common stock, with 25% vesting on the first anniversary of the grant date and the remaining shares vesting in 36 equal monthly installments. The awards were approved by the Board's Compen...
07-02 20:05
Tenax Therapeutics To Present Results From Phase 3 LEVEL Clinical Trial In Late-Breaking Clinical Science Session At ESC Congress 2026
Abstract recently submitted in anticipation of initial data analysis ahead of ESC Company expects to report topline LEVEL results in August CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company") announced today t...
07-02 19:03
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026
Tenax Therapeutics announced that results from its Phase 3 LEVEL clinical trial will be presented at the ESC Congress 2026 in Munich. The Company expects to report topline data in August, with the presentation scheduled for August 29. The trial evaluates TNX-103 for treating pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), a condition lacking approved treatments. Enrollment of over 230 patients was completed in...
07-02 11:00
Tenax Therapeutics Updates Executive and Employee Severance Protections
The latest announcement is out from Tenax Therapeutics ( ($TENX) ). On June 26,...
06-30 04:59
美股大行评级 | 瑞银上调超微公司目标价从455美元升至670美元，上调ARM目标价从260美元升至470美元；美银证券上调台积电目标价从490美元升至590美元
今日重点评级关注：Jones Trading：维持Definium Therapeutics"买入"评级，目标价从61美元升至74美元；韦德布什：维持Cerebras Systems"跑赢大市"评级，目标价从270美元升至280美元
06-25 11:32
美股大行评级 | 阿斯麦获美银、富国上调目标价最高至2345美元；Needham上调美光科技目标价从500美元升至1550美元
今日重点评级关注：Baird：维持Regenxbio"跑赢大市"评级，目标价从27美元升至32美元；古根海姆：维持Tenax Therapeutics"买入"评级，目标价从34美元升至40美元
06-23 13:48
Chardan Capital Initiates Coverage On Tenax Therapeutics with Buy Rating, Announces Price Target of $27
Chardan Capital analyst Gautam Chukka initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Buy rating and announces Price Target of $27.
06-22 20:47
美股大行评级 | Adobe惨遭18家大行下调目标价！CFRA首予SpaceX(SPCX)"卖出"评级，目标价115美元
今日重点评级关注：Piper Sandler：维持Tenax Therapeutics"超配"评级，目标价从20美元升至50美元；Tigress Financial：维持优步"买入"评级，目标价从110美元升至115美元
06-15 08:32
Piper Sandler Maintains Overweight on Tenax Therapeutics, Raises Price Target to $50
Piper Sandler analyst Yasmeen Rahimi maintains Tenax Therapeutics (NASDAQ:TENX) with a Overweight and raises the price target from $20 to $50.
06-13 00:38
U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle
U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle June 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe, Caseys General Stores and Oracle on Friday. HIGHLIGHTS * Adobe Inc ADBE.O : Baird cuts target pri
06-12 15:34
